-
Huahai broke out! FDA warning letter closed to win 5 blockbuster varieties
Time of Update: 2021-12-08
Data source: Mi Nei. com database, company announcement Recently, Huahai Pharmaceuticals announced heavy news: the southern Sichuan API base warning has been lifted, and sales in the US market are expected to resume .
-
Zai Lab Qingle second-line treatment of gastrointestinal stromal tumor phase 3 clinical failure
Time of Update: 2021-12-08
Recently, Zai Lab's partner Deciphera announced the targeted anticancer drug Qinlock (Chinese product name: Qingle®, generic name: ripretinib, Ripetinib) for the second-line treatment of gastrointestinal stromal tumor (GIST) INTRIGUE Phase 3 clinical trial Top-line results of the study .
-
GSK: Continue to deepen the field of central nervous system to bring better choices for patients
Time of Update: 2021-12-08
In addition, GSK has always adhered to the value of "patient-centered", not only bringing innovative drugs to China, but also actively participating in public welfare undertakings, helping China to improve its awareness and standardization of diagnosis and treatment in the fields of epilepsy, bipolar disorder and other diseases.
-
The secret quality assurance that the original research lenvatinib (Levima) cannot be imitated guarantees the efficacy and safety
Time of Update: 2021-12-07
Next, the editor will reveal the three high-quality ingenuity keys that the original lenvatinib cannot replicate from three aspects: the proportion of excipients, equipment cleaning, and the control of harmful impurities.
-
Johnson & Johnson announced the split!
Time of Update: 2021-12-07
Among them, the income of various segments of medical equipment business is as follows: Intervention solution revenue was US$957 million, a year-on-year increase of 13.
Among them, the income of various segments of medical equipment business is as follows: Intervention solution revenue was US$957 million, a year-on-year increase of 13.
-
The 4th domestically produced! Chia Tai Tianqing will take antipsychotic drugs that skyrocketed 30 times
Time of Update: 2021-12-07
Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product .
-
The next generation of "synthetic lethal" ATR inhibitors are being developed
Time of Update: 2021-12-07
In addition, in 2020, Merck announced in The Lancet the results of a clinical trial of Berzosertib combined with gemcitabine in the treatment of patients with advanced ovarian cancer.
In addition, Merck and Bayer's ATR inhibitors have been approved by NMPA and are currently in phase I clinical trials .
-
Shandong pharmaceutical company will win 4 billion oral hypoglycemic drugs
Time of Update: 2021-12-07
Figure 2: The current approval status of dapagliflozin tablets Source: One-click search on Mi Nei. com Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
-
Yangtze River has won the best-selling anti-ED drug
Time of Update: 2021-12-06
Figure 2: 2021E China city entity pharmacy terminal urinary system drug products TOP5 pattern Source: China City Entity Pharmacy Terminal of Meinenet Sildenafil citrate tablets are a major product among ED drugs.
-
The best-selling anti-gout drug!
Time of Update: 2021-12-05
TOP5 terminal anti-gout products in physical pharmacies in Chinese cities Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern Febuxostat tablets were developed by Japan's Teijin Pharmaceuticals and were approved for listing in the United States in 2009, and are now on the market in many countries and regions including China .
-
Eli Lilly initiates first head-to-head study of CGRP migraine drug
Time of Update: 2021-12-05
Last weekend, Eli Lilly announced the initiation of a phase 4 clinical trial to compare its monthly subcutaneous CGRP migraine drug Emgality with oral tablets Nurtec ODT for the preventive treatment of paroxysmal migraine (EM) .
-
1.7 billion injections of Bortezomib for injection!
Time of Update: 2021-12-05
Sales of terminal bortezomib in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern With the injection of boron Simcere bortezomib through assessment, the current assessment of the product through the enterprise has reached eight, including CTTQ, Yangtze River Pharmaceutical, Shijiazhuang Pharmaceutical Group, Qilu Pharmaceutical, medicine, and other Stockhausen .
-
Kangyuan Pharmaceutical takes the lead in imitating GSK's best-selling migraine drug
Time of Update: 2021-12-04
Figure 1: The latest product status of Kangyuan Pharmaceutical Source: CDE official website Sumatriptan Naproxen Sodium Succinate Tablets is the first approved combination prescription preparation of triptans and anti-inflammatory analgesics, which relieve migraines through different pharmacological mechanisms of action .
-
Progress: The development of a non-covalent BTK inhibitor (AS-1763) in clinical phase I
Time of Update: 2021-12-03
Bruton's tyrosine protein kinase (BTK) has been recognized as an effective drug target for the treatment of B-cell malignancies, but the emergence of clinical resistance to the first-generation covalent BTK inhibitors is becoming a serious problem .
-
Talking about the drug-like and pharmaceutical properties of innovative drugs
Time of Update: 2021-12-03
Provide new targets and theories for new drug discovery as the upstream basic research stage; use new targets and theories to combine Existing technologies form patents and candidate compounds are the new drug discovery stage; pre-clinical comprehensive evaluation, clinical evaluation, and industrialization process research for candidate drugs are the new drug development stage; registration on the basis of the foregoing is the listing stage .
-
The latest advances in cell signaling and communication in cancer
Time of Update: 2021-12-03
The specific epigenesis is that genetic elements regulate proliferation (such as growth factors, metabolism), apoptosis (such as cell cycle checkpoints, DNA repair checkpoints) ), differentiation, cell polarity, and extracellular matrix (ECM) modeling, angiogenesis, inflammation and inter-cell communication and the like .
-
Qilu has another 700 million cardiovascular injections!
Time of Update: 2021-12-03
Sales of terminal esmolol hydrochloride injection in Chinese public medical institutions in recent years (unit: 100 million yuan) Source: The terminal competition pattern of China's public medical institutions According to data from Menet.
-
The Tao and Techniques of "Drug Co-Crystal"
Time of Update: 2021-11-15
Prospects of drug co-crystals The research and development of drug co-crystals is not only to improve the physical and chemical properties of APIs, but more importantly, to use co-crystals as a new drug combination method to increase the value of drug combination to a greater extent .
-
In the rivers and lakes of Jin Yong, why is Yang Guo's "love flower poison" poisonous, and "Heartbreak" is really a medicine?
Time of Update: 2021-11-15
Figure 2 The mechanism of action and pharmacological effects of alkaloids in datura flower (love flower) 1.
; Research progress on the chemical constituents, pharmacological effects and clinical application of Dactylaceae; Chinese Traditional and Herbal Drugs Volume 47, Issue 19, October 2016 .
-
Shaanxi Kangcheng Pharmaceutical-Plant extraction and processing investment, welcome to cooperate!
Time of Update: 2021-11-15
The company is located in Jinghe Ecological Industrial Park, Shangzhou District, Shangluo City, Shaanxi Province, covering an area of 118 acres, with a total construction area of 70,000 square meters; of which, the area of production workshops and storage buildings is 44,000 square meters; the area of office and service buildings is 26,000 square meters; The total construction investment is 320 million yuan .
